Negative-pressure wound therapy (NPWT) was developed in the early 1990s and reported in 1997 by Argenta and Morykwas. Ignored at first, this technique progressively came to be considered as an outstanding advancement in reconstructive surgery. Several randomized controlled studies produced evidence for the effect of NPWT on promotion of granulation tissue formation and prevention of tissue damage and amputation. However, no important longitudinal study has yet produced clinical and economic data on the consequences of integrating NPWT into practice in multiple institutions. This prospective, comparative longitudinal study of NPWT as a clinical-practice innovation was conducted in 1,126 patients between March 2006 and June 2009 in 30 university and nonuniversity public and private hospitals in France. NPWT was proposed in a nonrandomized fashion for various clinical indications, and the patients were divided into two groups, one using NPWT, the second using standard care. Efficacy criteria were spontaneous closure, closure after surgical coverage using skin grafts or flaps, or achievement of 40% wound area regression. The results, observed in a pragmatic but not randomized study, are suggestive of a favorable impact of NPWT in multiple clinical situations. The significance of differences between surgical patients who underwent NPWT and those who did not was unclear, as NPWT had already been adopted by most of the surgical wards.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/wrr.12179 | DOI Listing |
J Plast Reconstr Aesthet Surg
November 2024
Bagcilar Training and Research Hospital, Department of Plastic, Reconstructive and Aesthetic Surgery, Istanbul, Turkey.
Objective: Autoimmune diseases are systemic conditions that can have negative effects on wound healing. The objective of the present study was to investigate the efficacy of combining bone marrow-derived mesenchymal stem cells (BM-MSCs), acellular dermal matrix (ADM), split-thickness skin graft (STSG), and negative-pressure wound therapy (NPWT) for treating patients with autoimmune diseases and chronic non-healing wounds.
Methods: Thirty-four patients with autoimmune diseases and non-healing chronic wounds of the lower extremities between 2012 and 2023 were included in the study.
Surg Today
December 2024
Department of Colorectal Surgery, Tochigi Cancer Center, 4-9-13 Yohnan, Utsunomiya, Tochigi, 320-0834, Japan.
Purpose: Recent findings suggest that utilizing negative pressure wound therapy (NPWT) concurrently with stoma closure may decrease the risk of incisional surgical site infection (iSSI). However, the specific impact of NPWT on iSSI after stoma closure remains unclear. This study investigated the impact of NPWT on SSI after stoma closure.
View Article and Find Full Text PDFEmerg Microbes Infect
December 2024
Institute of Virology, Philipps-Universität Marburg, 35043 Marburg, Germany.
Ebola virus (EBOV) transcription is essentially regulated via dynamic dephosphorylation of its viral transcription activator VP30 by the host phosphatase PP2A. The nucleoprotein NP has emerged as a third key player in the regulation of this process by recruiting both the regulatory subunit B56 of PP2A and its substrate VP30 to initiate VP30 dephosphorylation and hence viral transcription. Both binding sites are located in close proximity to each other in NP's C-terminal disordered region.
View Article and Find Full Text PDFWorld Neurosurg
December 2024
Chief, Division of neurosurgery, Department of Surgery, Howard University Hospital, 2041 Georgia Ave, Washington, DC, USA.
Background: Negative pressure wound therapy (NPWT) has been employed for post-surgical wound management across various disciplines, including spinal surgery. However, its efficacy in reducing wound infection rates following posterior thoracolumbar spine surgery remains uncertain.
Methods: A retrospective review was conducted at a single institution, examining 266 patients who underwent posterior thoracic, lumbar, or thoracolumbar spine surgery performed by one neurosurgeon.
Acta Diabetol
December 2024
Azienda Sanitaria Friuli Occidentale, Pordenone, Italy.
Aim: To assess the effects of several adjuvant therapies (AT) commonly used in the treatment of diabetic foot ulcers (DFU). The present meta-analysis was designed to support the development of the Italian Guidelines for the Treatment of Diabetic Foot Syndrome.
Methods: A Medline and Embase search were performed up to May 20th, 2024 collecting all RCTs including diabetic patients or reporting subgroup analyses on diabetic patients with DFU comparing AT with placebo/standard of care (SoC), with a duration of at least 12 weeks.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!